Human telomerase has been implicated in cell immortalization and cancer. Recent works suggest that telomerase confers additional function required for tumorigenesis that does not depend on its ability to maintain telomeres. This new action may influence tumor therapy outcomes by yet unraveled mechanisms. Here, we show that overexpression of the catalytic subunit of telomerase (hTERT) protects a maturation-resistant acute promyelocytic leukemia (APL) cell line from apoptosis induced by the tumor necrosis factor (TNF) or TNF-related apoptosis-inducing ligand (TRAIL) and not from apoptosis induced by chemotherapeutic drugs such as etoposide or cisplatin. Conversely, in these cells, TRAIL-induced cell death is magnified by alltrans retinoic acid (ATRA) treatment, independently of telomerase activity on telomeres. Of note, this response is subordinated neither to maturation nor to telomere shortening. This work underlines that retinoids and death receptor signaling cross-talks offer new perspectives for antitumor therapy.
Introduction
Human telomerase, a ribonucleoprotein that catalyses the synthesis and extension of telomeric DNA (Greider and Blackburn, 1985; Morin, 1989) , contributes to the stability of chromosome ends by compensating for replication-dependent telomere shortening (Lingner and Cech, 1998) . Usually silenced in normal somatic cells, telomerase is specifically activated in most malignant tumors, suggesting a key role in cell immortalization and carcinogenesis (Meyerson et al., 1997; Hahn et al., 1999) . Owing to this differential expression pattern in normal and tumors cells, telomerase has been proposed as a promising target for anticancer therapies. By taking advantage of the evergrowing knowledge on the multifunction telomerase macromolecular complex, numerous anticancer strategies targeting telomerase components or telomeric DNA have been proposed (Helder et al., 2002; Mergny et al., 2002) . The latter include antisense oligonucleotides against the template region of the RNA component of the human telomerase (hTR), traditional reverse transcriptase inhibitors targeting the activity of the catalytic subunit (hTERT), and agents able to promote or stabilize G-quadruplex formation in telomeric DNA. Alternatively, we recently proposed telomerase expression as a selectively targetable mechanism for retinoid therapy, even in all-trans retinoic acid (ATRA)-maturation-resistant leukemia cells (Pendino et al., 2001) . Noteworthy, the main limitation of any of these strategies is the time necessary to shorten telomeres, thus to produce effects detrimental to tumor cell growth.
Recent findings indicate that telomerase confers additional function required for tumorigenesis that does not depend on its ability to maintain telomeres (Stewart et al., 2002) . Furthermore, telomerase contributes to install an immortal cell phenotype by preventing apoptosis, and may play a role in cellular resistance to anticancer drugs (Kondo et al., 1998; Fu et al., 1999 Fu et al., , 2000 Kushner et al., 2000) . In keeping with this notion, targeting telomerase expression could well affect events in the regulation of cell proliferation and/or apoptosis, independently of reduction of telomere length linked to the number of cell generation.
In this work, the NB4-LR1 maturation-resistant cell line was used in order to explore the relationship between telomerase activity (TA) and sensitivity to apoptosis. The rationale for this was that if telomerase is endowed with an antiapoptotic function, ectopic expression of hTERT might protect these cells from druginduced apoptosis. Conversely, ATRA pretreatment previously shown to downregulate hTERT independently from maturation in these cells (Pendino et al., 2001 ) might sensitize them to apoptosis. Based on this hypothesis, functional in vitro studies were performed on the parental NB4-LR1 cells, the retroviral transduced NB4-LR1/hTERT-GFP cells expressing both hTERT protein and GFP reporter from the same transcript, and the NB4-LR1/GFP cells infected with the control virus and expressing only the GFP protein. In mammalian cells, apoptosis can be initiated through two major pathways: (1) the mitochondrial-mediated pathway involving cytochrome c-release from the mitochondria and activation of the upstream caspase-9 (Green and Reed, 1998 ) also known as the 'intrinsic' pathway and, (2) the receptor-mediated pathway referred to as the 'extrinsic' pathway, which involves members of the tumor necrosis factor (TNF) family of death receptors (DR), including TNF-related apoptosis-inducing ligand (TRAIL) receptors DR4 and DR5, which activate the upstream caspase-8 (Ashkenazi and Dixit, 1998) . Thus, we investigated responses to apoptotic inducers known to use these two pathways: drugs as etoposide or cisplatin and TNF/TRAIL, respectively.
Results and discussion

Overexpression of hTERT protects NB4-LR1 cells from TRAIL-induced apoptosis
The effect of hTERT expression in the susceptibility of leukemia cells to anticancer drugs was evaluated comparing the effects of drugs (cisplatin, etoposide) and a death receptor ligand (TRAIL) known to induce apoptosis, but through distinct pathways, in NB4-LR1, the retroviral transduced NB4-LR1/hTERT-GFP, and NB4-LR1/GFP cells. The maturation-resistant human acute promyelocytic leukemia (APL) cell line NB4-LR1 (Lanotte et al., 1991; Duprez et al., 1992; Ruchaud et al., 1994) , the subline NB4-LR1/hTERT-GFP (Pendino et al., 2001) , expressing both hTERT protein and the green fluorescent protein (GFP) reporter from the same transcript, and the NB4-LR1/GFP subline, expressing only the GFP control vector, were described previously (Lanotte et al., 1991; Pendino et al., 2002) . NB4-LR1/ hTERT-GFP subline escapes death induced by longterm ATRA treatment (Pendino et al., 2001 (Pendino et al., , 2002 .
As shown in Figure 1 , NB4-LR1 and NB4-LR1/GFP cells were almost equally sensitive to cisplatin, etoposide, or TRAIL ligand. The NB4-LR1/hTERT-GFP cells exhibited an increased sensitivity to cisplatin or etoposide. In contrast, hTERT fully protects these cells from TRAIL-induced toxicity. To exclude the possibility that this protective effect was restricted to TRAIL toxicity, we analysed the cell response to TNFa, another DR ligand. Similarly, hTERT protected NB4-LR1 cells from TNFa-induced toxicity ( Figure 1) . As all the cell lines displayed identical growth kinetics, the observed resistance to TRAIL or TNFa does not seem to result from alteration in the cell growth regulation (data not shown).
To determine whether this protective effect of hTERT overexpression on TRAIL-induced toxicity was due to the decrease of apoptosis, terminal deoxynucleotidyl transferase (TUNEL) assay and DAPI staining were performed. The two analyses confirmed that the ectopic expression of telomerase exerted a protection against TRAIL by decreasing apoptosis (Figure 2a ). Telomerase abolishes TRAIL-induced apoptosis C Dudognon et al form functional death-inducing signaling complex and trigger apoptotic signals. TRAIL also binds to DcR1 and DcR2 but as they lack functional cytoplasmic death domain they serve as decoy receptors by diminishing apoptotic signals. As it was postulated that differential expression of TRAIL receptors may determine whether a cell is -or is not -resistant to TRAIL (Golstein, 1997; Pan et al., 1997; Sheridan et al., 1997) , the surface expression of TRAIL receptors was assessed comparatively in each cell line by flow cytometry using anti-DR5/DR4/DcR1/DcR2 antibodies (Figure 2b ). FACS analyses showed that DcR1 was not measurably detected in either cell line and that DcR2 has a very low expression. The three cell lines expressed DR5 and DR4 on the surface. Thus, no difference in the expression of TRAIL receptors between the cell lines could account for the protection against TRAIL when hTERT is overexpressed.
TRAIL receptor expression in NB4-LR1, NB4-LR1/GFP and NB4-LR1/hTERT-GFP cells
ATRA prones maturation-resistant cells to TRAIL-induced apoptosis
In the maturation-resistant NB4-LR1 and NB4-LR1/ GFP cells, prolonged ATRA treatment represses endogenous telomerase. As expected, ectopically expressed hTERT is not affected by ATRA treatment in the NB4-LR1/hTERT-GFP cell line (Pendino et al., 2001 ). The three cell lines were analysed comparatively for their susceptibility to TRAIL-induced apoptosis (TUNEL assay and DAPI staining) and cell growth (WST-1 assay), following a 9-day ATRA (1 mM) treatment (Figure 3a) . By 9 days of ATRA treatment, TA of both NB4-LR1 and the retrovirally transduced control NB4-LR1/GFP cells decreases to less than 20% of the activity in the untreated cells without any changes of the mean length of telomeres and growth rate (Figure 3a and data not shown). While TRAIL-induced apoptosis was significantly enhanced in both NB4-LR1 and NB4-LR1/GFP cells by ATRA pretreatment (ATRAdependent hTERT downregulation), apoptosis was significantly suppressed in ATRA pretreated NB4-LR1/hTERT-GFP cells that do preserve the ectopic expression of hTERT (Figure 3a) . Note that the sensitivity of all cell lines to cisplatin, or etoposide was not modified by ATRA pretreatment (data not shown), suggesting that the increased sensitivity of the NB4-LR1/hTERT-GFP cells to cisplatin or etoposide represents likely an intrinsic property of this cell line independent of telomerase expression. There are apparently contradictory reports regarding the effect of hTERT on cisplatin-induced apoptosis and in general in DNA-damaged induced cell death (Kondo et al., 1998; Folini et al., 2000; Lu et al., 2001; Ludwig et al., 2001; Gorbunova et al., 2002; Yuan and Mei, 2002; Rubio et al., 2002 Rubio et al., , 2004 . These controversial results obtained in these studies, including ours, could be tentatively explained by the fact that the cell response to genotoxic stress may depend on the combination of stress of distinct nature, the presence of telomeric proteins which can interfere with some types of DNA repair and on the length of the shortest telomere and the ability of telomerase to elongate short telomeres, as recently demonstrated (Rubio et al., 2002 (Rubio et al., , 2004 . Note also that the methods used to regulate TA vary in these several publications. Altogether, these results showed that hTERT might specifically target an effector step of the death receptorsignaling pathway to protect against TRAIL-induced cell death.
Initial action of telomerase on cell fate unrelated to telomere maintenance
The rationale for a 9-day ATRA pretreatment stemmed from our previous demonstration that, in both NB4-LR1 and NB4-LR1/GFP cells, it downregulates hTERT gene transcription and decreases hTERT reverse transcriptase activity (15% of TA relative to untreated cells determined by the telomeric repeat amplification protocol (TRAP) assay), down to levels incompatible with chromosome end maintenance (Pendino et al., 2001) . The above new findings led us to propound the view that hTERT may act also faraway from telomeres, possibly at the inner plasma membrane onto the death-receptor transducing machinery. Therefore, there was no longer obvious reason to keep the notion (1) that the antiapoptotic function of hTERT and the transcriptase activity are correlated, and thus, (2) that ATRA and TRAIL cooperate by means of a decrease of the nuclear function of hTERT previously observed. Therefore, we tested the effect of ATRA and TRAIL in conditions where hTERT nuclear function (checked by the TRAP assay) showed only moderate decrease. When ATRA and TRAIL were applied simultaneously for 48 h, TRAP assay demonstrates 90-100% of TA relative to untreated cells (Figure 3b) . Importantly, we observed comparable rate of apoptosis in both NB4-LR1 and NB4-LR1/GFP cells, whatever TA (determined by the TRAP assay) is low (15% in ATRA pretreatment, see Figure 3a ) or high (100%, cotreatment, see Figure 3b ). These results revealed an early action of ATRA on telomerase function, unrelated to hTERT downregulation and its reverse transcriptase activity as measured with the TRAP assay. As already observed in the ATRA pretreatment experiment, the ectopic expression of hTERT has a protective effect on this synergistic response supporting the involvement of a telomerase-dependent mechanism in this response. Note that ATRA treatment does not affect the expression of TRAIL receptors in the three cell lines (data not shown). It has been shown that telomerase can be regulated not only via transcriptional mechanisms but also by posttranslational and post-traductional mechanisms (Aisner et al., 2002; Mergny et al., 2002) . A possible explanation for the synergistic effect of ATRA and TRAIL observed in the absence of hTERT downregulation is that ATRA may affect directly the antiapoptotic function of telomerase by interfering with its post-traductional regulation or its cellular localization without altering its expression and its ability to elongate telomeres as measured in vitro by the TRAP assay. Experiments are underway in our laboratory to test this hypothesis.
Telomerase abolishes TRAIL-induced apoptosis C Dudognon et al
In addition, to fully demonstrate the non-nuclear activity of telomerase in the control of TRAIL-induced apoptosis, and to determine the domains of hTERT wherefrom this protein could exert its protective action, further experiments are needed. It includes investigations on the effects of hTERT constructs defective in telomere elongation activity.
Concluding remarks
It was recently shown that telomerase might have a role in chromosome end protection that is independent of its ability to elongate telomeres. Here, we show that a new function of telomerase might occur far away from chromosome directly on one specific apoptotic signaling, the death receptor-induced pathway. These findings The specific surface expression of DR4, DR5, DcR1, and DcR2 in the various NB4-LR1 variants was analysed by indirect staining using primary mouse anti-human DR4, DR5, DcR1, and DcR2 antibodies (50 mg/ml) (all from Alexis, Coger, France), respectively, followed by incubation with an allophycocyaninconjugated anti-mouse IgG (286 ng/ml) (BD Pharmingen, Le Pont de Claix, France). The surface staining was determined using the FACS system (Becton Dickinson). Shadowed histogram represent negative control, clear histogram represent untreated cells. DR4, DR5, DcR1 and DcR2 expression are indicated by green, red, blue, and yellow histograms, respectively
Telomerase abolishes TRAIL-induced apoptosis C Dudognon et al open a wide promising field of investigation on both the antiapoptotic function of telomerase and the mechanism whereby ATRA could regulate this function. At the present time it is difficult to hazard a conjecture on this mechanism, but it is likely dissociated from the late downregulation of hTERT that affect telomere length, and could rather involve fast developing post-translational and post-traductional mechanisms (Aisner et al., 2002; Mergny et al., 2002) . Note that apoptosis is fully suppressed only when hTERT is ectopically overexpressed (NB4-LR1/hTERT). It may mean that oncogenic events that strongly upregulate telomerase, may have as primer consequences to counteract physiological receptor-dependent apoptotic signaling, allowing tumor progression. This new function of telomerase can be mediated by its action in the regulation of antiapoptotic and growth controlling genes independently of telomere functions as recently suggested (Smith et al., 2003) . This newly identified action and the late telomere-dependent suppression of senescence could well together contribute to engender immortalized cell progenies. Of note, while telomerase could well contribute to tumor progression by inhibiting physiological control of cell fate, its antiapoptotic function could not significantly affect antitumor chemotherapy (etoposide, cisplatin). These observations as well as previously reported studies additionally demonstrate that telomerase may have broad biological consequences in addition to its essential function for telomere elongation and maintenance and thereby its activation can explain some not yet understood drugresistance phenotype. Clearly, facing this new function of telomerase in the control of cell fate, new pharmacological investigations tracking telomerase outside telomere environment are required.
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